These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33300554)

  • 21. MicroRNA Methylation in Colorectal Cancer.
    Kaur S; Lotsari-Salomaa JE; Seppänen-Kaijansinkko R; Peltomäki P
    Adv Exp Med Biol; 2016; 937():109-22. PubMed ID: 27573897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.
    Bond CE; Bettington ML; Pearson SA; McKeone DM; Leggett BA; Whitehall VL
    BMC Cancer; 2015 Jan; 15():20. PubMed ID: 25613750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
    Dercle L; Lu L; Schwartz LH; Qian M; Tejpar S; Eggleton P; Zhao B; Piessevaux H
    J Natl Cancer Inst; 2020 Sep; 112(9):902-912. PubMed ID: 32016387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
    Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
    Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
    Barras D; Missiaglia E; Wirapati P; Sieber OM; Jorissen RN; Love C; Molloy PL; Jones IT; McLaughlin S; Gibbs P; Guinney J; Simon IM; Roth AD; Bosman FT; Tejpar S; Delorenzi M
    Clin Cancer Res; 2017 Jan; 23(1):104-115. PubMed ID: 27354468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
    Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment.
    Ma Y; Li J; Zhao X; Ji C; Hu W; Ma Y; Qu F; Sun Y; Zhang X
    Eur J Med Res; 2024 Mar; 29(1):207. PubMed ID: 38549156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway.
    Sakai E; Fukuyo M; Ohata K; Matsusaka K; Doi N; Mano Y; Takane K; Abe H; Yagi K; Matsuhashi N; Fukushima J; Fukayama M; Akagi K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2016 Apr; 138(7):1634-44. PubMed ID: 26510091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of DNA methylation-driven genes for predicting the prognosis of patients with colorectal cancer.
    Fu B; Du C; Wu Z; Li M; Zhao Y; Liu X; Wu H; Wei M
    Aging (Albany NY); 2020 Nov; 12(22):22814-22839. PubMed ID: 33203797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
    Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
    World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype.
    Hiew MSY; Cheng HP; Huang CJ; Chong KY; Cheong SK; Choo KB; Kamarul T
    J Biomed Sci; 2018 Jul; 25(1):57. PubMed ID: 30025541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis.
    Hur K; Toiyama Y; Takahashi M; Balaguer F; Nagasaka T; Koike J; Hemmi H; Koi M; Boland CR; Goel A
    Gut; 2013 Sep; 62(9):1315-26. PubMed ID: 22735571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
    Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
    Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression.
    Ye YP; Wu P; Gu CC; Deng DL; Jiao HL; Li TT; Wang SY; Wang YX; Xiao ZY; Wei WT; Chen YR; Qiu JF; Yang RW; Lin J; Liang L; Liao WT; Ding YQ
    Oncotarget; 2016 Sep; 7(38):61312-61324. PubMed ID: 27494869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
    Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer.
    Szmida E; Karpiński P; Leszczynski P; Sedziak T; Kielan W; Ostasiewicz P; Sasiadek MM
    J Appl Genet; 2015 May; 56(2):185-92. PubMed ID: 25366420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The integrated pathway of TGFβ/Snail with TNFα/NFκB may facilitate the tumor-stroma interaction in the EMT process and colorectal cancer prognosis.
    Li H; Zhong A; Li S; Meng X; Wang X; Xu F; Lai M
    Sci Rep; 2017 Jul; 7(1):4915. PubMed ID: 28687755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.